Brand Finance logo

Sinopharm is most valuable Chinese pharmaceuticals brand with 11% rise in value

01 July 2022
  • Sinopharm retains its position as most valuable pharmaceuticals brand in China, valued at US$3.5 billion
  • Guangzhou Pharmaceutical is the fastest growing brand in the ranking, more than doubling in value since 2020
  • SPH is among the top 3 pharmaceutical brands in China
  • New entrant Jointown Pharmaceutical grew its footprint amid COVID-19 conditions
  • Tong Ren Tang achieved 40% brand value growth, jumps 3 positions in the ranking as one of the top 10 Chinese pharma brands

View the full Brand Finance Chinese Pharma 15 report here

Sinopharm retains its position as most valuable pharmaceutical brand in China, valued at US$3.5 billion

Sinopharm (brand value up 11% to US$3.5 billion) continues to be the most valuable Chinese pharmaceuticals brand, according to a new report by the leading brand valuation consultancy, Brand Finance. The brand plays an important role in the Chinese public health landscape by developing and deploying one of the world’s most used COVID-19 vaccines. Sinopharm is forming strategic alliances with local pharma brands to tackle the spread of the virus by strengthening its supply chain and distribution network and thus increasing access to healthcare across China. The brand invested in research and development to create the Sinopharm vaccine, which was the first non-Western vaccine to be granted approval by the World Health Organisation (WHO) in 2021 and has been administered widely across China and internationally.

Every year, Brand Finance puts 5,000 of the world’s biggest brands to the test, and publishes around 100 reports, ranking brands across all sectors and countries. The Chinese pharmaceutical industry’s top 15 most valuable and strongest brands in the world are included in the annual Brand Finance Chinese Pharma 15 ranking.

The aggregate value of top Chinese pharmaceutical brands grows by 18% year-on-year as brands expand in international markets. Chinese pharma brands are playing an instrumental role during the pandemic to develop and administer vaccines across the nation and deploy humanitarian aid to other nations. The brands have stayed current in the post-COVID-19 economy by adapting to current market conditions by expanding their reach into new markets and new customer segments. 

Scott Chen, Managing Director, Brand Finance China, commented:

“Chinese pharmaceutical brands achieved strong brand value growth despite uncertain business conditions amidst the COVID-19 pandemic. Brands in the ranking have invested in research to introduce new offerings for customers. As the importance of the healthcare industry increases, investments made at the height of the pandemic are paying off.”

Guangzhou Pharmaceutical is the fastest growing brand in the ranking, more than doubling in value since 2020

Guangzhou Pharmaceuticals Holdings achieved brand value growth of 147% since 2020. Over the course of 2021, the brand value grew by 42% to US$2.1 billion. The pharma brand is best known for its global supply chain and digital management of its cloud platform that result in efficient delivery of healthcare. Additionally, the brand led efforts to reduce the impact of COVID-19 at the height of the pandemic and contributed positively to the community tackling pandemic induced obstacles. The brand’s impact on the healthcare sector continues to grow as it undertakes market expansion activities in new markets like Pakistan, Angola, and Mozambique to name a few.  

GPC has been deeply engaged in brand building, innovatively implementing the dual-brand strategy in the Chinese market which in turn have promoted the rapid opening of the national market for branded products. In the international market, Guangzhou Pharmaceutical has put forward the concept of modernisation and internationalisation of traditional Chinese medicine at the beginning of this century. In recent years, Guangzhou Pharmaceutical has strengthened its cooperation with Fortune 500 companies through the World Economic Forum and other international conferences.

SPH is among the top 3 pharmaceutical brands in China

SPH (brand value up 7% to US$1.5 billion) is the third most valuable Chinese pharmaceutical brand in the ranking this year. The brand focuses on pharma distribution and retail in the Chinese market as well as overseas. Apart from manufacturing, the brand also focusses on value added services such as logistics and support services to increase the reach of the product offerings. The brand invested its resources in research and development for new medical innovations during the pandemic.

New entrant Jointown Pharmaceutical grew its footprint amid COVID-19 conditions

New entrant in the ranking Jointown Pharmaceutical (brand value of US$457 million) was able to expand its operations internationally amid COVID-19 conditions and provide healthcare equipment and COVID protective gear to markets outside China to help contain the spread of the virus. The brand formed a strategic partnership with the logistics brand Kuehne+Nagel to help with efficient distribution of vaccines and protective gear. After a surge in demand for medicines and healthcare equipment, the brand is also increasing its manufacturing capabilities by constructing new storage and warehousing facilities.

Tong Ren Tang achieved 40% brand value growth, jumps 3 positions in the ranking as one of the top 10 Chinese pharma brands

Tong Ren Tang (brand value up 40% to US$289 million) jumped up 3 positions in the Brand Finance Chinese Pharma 15 ranking. The brand is among the top 10 Chinese pharmaceutical brands, it achieved an impressive 108% brand value growth since 2020. The brand’s reputation as a pioneer in Chinese traditional medicine is growing as it expands into adjacent sectors including wellness, and food and beverages. The brand has been actively engaging younger Gen Z consumers with its new upscale coffee shop in Beijing with a wide number of food and beverage offerings across Western and Chinese herbology.

View the full Brand Finance Chinese Pharma 15 report here

ENDS

Note to Editors

Every year, leading brand valuation consultancy Brand Finance puts 5,000 of the world’s biggest brands to the test, and publishes around 100 reports, ranking brands across all sectors and countries. China’s top 15 most valuable and strongest pharmaceutical brands are included in the Brand Finance Chinese Pharma 15 ranking.

Brand value is understood as the net economic benefit that a brand owner would achieve by licensing the brand in the open market. Brand strength is the efficacy of a brand’s performance on intangible measures relative to its competitors.

The full ranking, additional insights, charts, more information about the methodology, and definitions of key terms are available in the Brand Finance Chinese Pharma 15 report.

Media Contacts

Michael Josem
Associate Communications Director
Brand Finance
Shreya Hiwale
Communications Executive
Brand Finance
T:
Candice Menoita
Communications Executive
Brand Finance

About Brand Finance          

Brand Finance is the world’s leading brand valuation consultancy. Bridging the gap between marketing and finance, Brand Finance evaluates the strength of brands and quantifies their financial value to help organisations of all kinds make strategic decisions.

Headquartered in London, Brand Finance has offices in over 20 countries, offering services on all continents. Every year, Brand Finance conducts more than 5,000 brand valuations, supported by original market research, and publishes nearly 100 reports which rank brands across all sectors and countries.

Brand Finance is a regulated accountancy firm, leading the standardisation of the brand valuation industry. Brand Finance was the first to be certified by independent auditors as compliant with both ISO 10668 and ISO 20671, and has received the official endorsement of the Marketing Accountability Standards Board (MASB) in the United States.

Disclaimer

Brand Finance has produced this study with an independent and unbiased analysis. The values derived and opinions presented in this study are based on publicly available information and certain assumptions that Brand Finance used where such data was deficient or unclear. Brand Finance accepts no responsibility and will not be liable in the event that the publicly available information relied upon is subsequently found to be inaccurate. The opinions and financial analysis expressed in the study are not to be construed as providing investment or business advice. Brand Finance does not intend the study to be relied upon for any reason and excludes all liability to any body, government, or organisation.

The data presented in this study form part of Brand Finance's proprietary database, are provided for the benefit of the media, and are not to be used in part or in full for any commercial or technical purpose without written permission from Brand Finance.

Get in Touch

Message